Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone-Reference-Cited by-同舟云学术

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone

Published:2021-01-01 Issue:1 Volume:23 Page:70-77
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Danne Thomas¹,Joish Vijay N.²,Afonso Marion³,Banks Phillip²,Sawhney Sangeeta²,Lapuerta Pablo²,Davies Michael J.²,Buse John B.⁴,Lin Dee⁵,Reaney Matthew⁶,Guillonneau Sophie³,Snoek Frank J.⁷,Bailey Timothy S.⁸,Polonsky William H.⁹

Affiliation:

1. Department for General Pediatrics, Diabetes, Endocrinology, and Clinical Research, Children's Hospital Auf der Bult, Hannover Medical School, Hannover, Germany.

2. Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.

3. Sanofi S.A., Paris, France.

4. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

5. Sanofi US, Inc., Bridgewater, New Jersey, USA.

6. Sanofi, Guildford, United Kingdom.

7. Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

8. AMCR Institute, Escondido, California, USA.

9. Behavioral Diabetes Institute, San Diego, California, USA.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism